Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Nvidia, Droplet Biosciences partner on AI-accelerated genomic analysis for lymph-based liquid biopsy testing
Technology collaboration, oncology, AI/ML, diagnostics, genomic analysis - Read more

Blackstone Life Sciences, Teva Pharmaceutical partner on gut disease drug duvakitug with $400M commitment
Equity investment, autoimmune, antibody, milestone payments - Read more

Codexis signs agreement to manufacture 50g siRNA using ECO Synthesis platform for cardiovascular therapeutic
Manufacturing agreement, siRNA, cardiovascular, preclinical development - Read more

iLoF, Bluepharma collaborate to deploy AI-powered Optomics platform for accelerated drug development
Strategic collaboration, AI/ML, drug discovery, manufacturing, personalized medicine - Read more

Sanofi, Chia Tai Tianqing Pharmaceutical license JAK/ROCK inhibitor rovadicitinib, $135M upfront, $1.395B milestones
Licensing deal, autoimmune, small molecule, milestone payments - Read more

The pathway to FDA can be difficult to navigate when precedent is limited, and frameworks are thin.

Facet specializes in helping emerging biotech teams understand what your program must demonstrate, how regulators are likely to evaluate the evidence, and what constitutes a viable, and ultimately, approvable, path forward.

It’s a regulatory strategy that starts where it should: with your science and your goals. Not the other way around.

Book a free 30-minute intro session with Facet → click here

Akeso's cadonilimab achieves 100% 24-month survival in complete responders for recurrent metastatic cervical cancer Ph2 trial
Antibody, cancer, monoclonal antibody, cervical cancer, PD-L1 - Read more

ARPA-H launches $158M program for first-ever lymphatic system drug development
Lymphatic system, platform technology, small molecule, metabolic diseases - Read more

Theolytics awarded €8M ($9.3M) Horizon Europe grant for ovarian cancer study
Oncology, oncolytic immunotherapy, ovarian cancer, clinical-stage - Read more

Can-Fite BioPharma raises $4M warrant exercise for R&D and clinical trials
Oncology, small molecule, inflammatory diseases, clinical-stage - Read more

MAIA Biotechnology raises $30M public offering for clinical trials, targeted cancer immunotherapies
Cancer, targeted immunotherapies, clinical-stage, oncology - Read more

UK invests $64M in NHS equipment to expand clinical trial access to underserved communities
Clinical trials, strategic, operational, investment - Read more

Roche invests $484M in South Korea to establish global clinical trial ecosystem
Research collaboration, clinical trials, R&D, manufacturing, equity investment - Read more

RadNet snaps up Gleamer for €215M ($249.6) upfront to bolster its AI imaging portfolio
AI imaging, oncology, strategic, major transaction - Read more

Ireland maintains biopharma investment appeal despite US tariff uncertainty and geopolitical trade tensions, says IDA Ireland
Manufacturing, supply chain, strategic, geopolitical risk - Read more

FDA grants Vanda Pharmaceuticals landmark hearing for HETLIOZ jet lag approval, first in 40 years
Small molecule, sleep disorder, regulatory, strategic - Read more

Prime Medicine sees potential FDA approval for PM359 gene therapy based on 2-patient CGD study alone
Gene editing, rare disease, regulatory, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Bayer forecasts accelerating Xarelto, Eylea declines in 2026 amid generic and biosimilar competition pressures
Small molecule, cardiovascular, financial, competitive, revenue impact - Read more

Bristol Myers Squibb, J&J, AstraZeneca, GSK pressure Trump to withdraw CMS international drug pricing proposals
Cell and gene therapy, rare disease, regulatory, financial - Read more

FDA issues second untitled letter to Novo Nordisk over misleading Ozempic advertising claims
GLP-1 receptor agonist, diabetes, regulatory, operational - Read more

FDA places partial hold on PepGen's DM1 trial due to preclinical toxicology data concerns
Antisense oligonucleotide, rare disease, regulatory, operational - Read more

Ono's Deciphera Pharmaceuticals drops early-stage pan-RAF inhibitor DCC-3084 from pipeline for strategic reasons
Small molecule, oncology, strategic, pipeline discontinuation - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here